The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)

The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lu-PSMA

The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA

Multicentric, observational, single arm, prospective, study.

All patients will undergo imaging assessments according to clinical practice or to Lu-PSMA Tumor Institute of Romagna (IRST) 185.03 protocol, as follows:

• Baseline, before the treatment with Lu-PSMA, CT and WB-MRI will be performed
• At the end of treatment with Lu-PSMA, CT and WB-MRI will be performed
• In post-treatment follow-up every 4 months, until progression or for 1 year, CT and WB-MRI will be performed.

Patients participating in this observational study will not be subjected to any additional procedure that falls outside the clinical practice or the study 185.03 Lu-PSMA trial at IRST.

Inclusion Criteria:

- Patients with mCRPC enrolled in the Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, performing baseline CT and WB-MRI examinations and at least one CT and WB-MRI re-evaluation.

Exclusion Criteria:

• no exclusion criteria